AGIO
Agios Pharmaceuticals, Inc.
There isn't enough reported data to score AGIO yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AGIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AGIO's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AGIO PE Valuation
AGIO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AGIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect AGIO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AGIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.33 | +$0.37 |
| Q2 2026 | -$7.02 | -162% |
| Q1 2026 | -$7.26 | -163% |
| Q4 2025 | -$7.12 | -161% |
| Q3 2025 | -$6.70 | -159% |
| Q2 2025 | $11.30 | +$17.79 |
| Q1 2025 | $11.54 | +$17.85 |
| Q4 2024 | $11.64 | +$17.97 |
AGIO lost $6.33 per share over the past year, about the same as its loss the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AGIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.4M | +330% |
| Q2 2026 | $44.7M | +259% |
| Q1 2026 | $20.7M | +138% |
| Q4 2025 | $20M | +86% |
| Q3 2025 | $12.9M | +44% |
| Q2 2025 | $12.5M | +45% |
| Q1 2025 | $8.7M | +6.6% |
| Q4 2024 | $10.7M | +51% |
AGIO has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -139% | +768 points |
| Q2 2026 | -247% | +773 points |
| Q1 2026 | -530% | +692 points |
| Q4 2025 | -609% | +556 points |
| Q3 2025 | -907% | +240 points |
| Q2 2025 | -1020% | +208 points |
| Q1 2025 | -1222% | -98 points |
| Q4 2024 | -1165% | +331 points |
AGIO's operating margin was −139% last quarter, up 768 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over AGIO on profitability, with a higher operating margin.
AGIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$60.4M | +$29.3M |
| Q2 2026 | -$58.5M | +$19.5M |
| Q1 2026 | -$119.7M | -$7.4M |
| Q4 2025 | -$97.3M | +$36.8M |
| Q3 2025 | -$89.7M | -$5.1M |
| Q2 2025 | -$78M | -$5.3M |
| Q1 2025 | -$112.3M | -$12.2M |
| Q4 2024 | -$134.1M | -$61.4M |
AGIO has burned cash in almost every quarter: −$336M over the past year, against −$414M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AGIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
AGIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +219K shares |
| 1 year | +2.7% | +1.6M shares |
| 3 years | +7% | +3.9M shares |
| 5 years | +4.7% | +2.7M shares |
| Available history | -0.5% | -287K shares |
AGIO has 60M diluted shares, up 2.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | $19M |
| Q3 2021 | $254.4M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AGIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AGIO Net Leverage
AGIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AGIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.7 | Neutral |
| Stochastic | 23.0 | Neutral |
AGIO's weekly RSI is 49 (neutral) and its Stochastic is 23 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AGIO PE vs Healthcare Sector
| Metric | AGIO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AGIO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AGIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.0 | 0.8% below |
| 20 week MA | $33.7 | 5.6% below |
| 50 week MA | $30.9 | 2.7% above |
| 100 week MA | $32.8 | 3.1% below |
| 200 week MA | $32.4 | 1.9% below |
AGIO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AGIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.5 | $45.2 | -6.9% |
| 2021 | $45.2 | $35.8 | -21% |
| 2022 | $35.8 | $27.0 | -25% |
| 2023 | $27.0 | $22.3 | -18% |
| 2024 | $22.3 | $33.4 | +50% |
| 2025 | $33.4 | $28.0 | -16% |
| 2026 YTD | $28.0 | $31.8 | +13% |
AGIO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.